Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
77 Leser
Artikel bewerten:
(0)

Lung Cancer Alliance Comments on CDC's New Ad Campaign

Calls For Inclusion of Low Dose CT Screening For Those At High Risk For Lung Cancer

WASHINGTON, March 16, 2012 /PRNewswire-USNewswire/ --Today, Lung Cancer Alliance (LCA) said that the new anti-tobacco campaign just launched by the Centers for Disease Control and Prevention (CDC) is an important revitalization of the efforts to prevent young people from smoking and encourage all who do smoke to quit.

LCA President and CEO, Laurie Fenton Ambrose said, "this is among our top national public health priorities and we have to persist in our efforts to protect our children and loved ones from the scourge of big tobacco."

Moreover Fenton Ambrose continued, "the timing of this effort could not be better as we now have scientific validation, provided by the National Cancer Institute (NCI) last year, that offering the life saving benefit of CT screening to those who heed this call to quit could save their lives."

The large randomized controlled trial initiated by NCI in 2003 was terminated last year as soon as it became evident that screening high risk smokers and former smokers with CT scans could detect lung cancer at its earliest stage and be more effective in reducing lung cancer deaths than mammography screening for breast cancer or PSA testing for prostate cancer.

An actuarial analysis conducted by Milliman in 2010 estimated that the number of lives saved could be as high as 70,000 people a year.

In a letter to Secretary Kathleen Sebelius, Surgeon General Regina Benjamin, and CDC Director Thomas Frieden, Fenton Ambrose emphasized that "the broader agenda" being considered under this campaign has a new tool in its arsenal and that tool is low dose CT screening, which can detect life threatening tobacco-related disease at earlier and more curable stages. Research also shows that CT screening can increase quit rates.

Shortly after the release of the results of the NCI study, the National Comprehensive Cancer Network (NCCN), the leading authority on evidence based guidelines for cancer detection and treatment, gave CT screening its highest level of endorsement. A major national health insurer also announced it would cover CT screening for those at high risk for lung cancer.

Last month, LCA issued the National Framework for Excellence in Lung Cancer Screening and Continuum of Care, to help incorporate safe, effective, and equitable CT screening, consistent with the highest standards of care within public health.

"The Framework lays it all out," said Fenton Ambrose. "What are the rights of the public, what standards should be followed by screening sites, and how do we collect and manage data on outcomes so we can continuously improve and refine the process as we learn more and as advances in imaging and molecular detection occur."

The Framework includes smoking cessation as a key part of the screening process. It also calls on those who are screened and on screening sites to donate data and biomedical specimens to further research into biomarkers and precancerous conditions that could shed more light on non-smoking related lung cancers, which are now the sixth leading cause of cancer death.

To view the letter go to www.lungcanceralliance.org.

Lung Cancer Alliance, www.lungcanceralliance.org, provides support and advocacy for those living with or at risk for lung cancer. LCA is committed to reversing decades of stigma and neglect by empowering those with or at risk for lung cancer, elevating awareness and changing health policy at both the federal and state level.

Media Contact:
Kay Cofrancesco
kay@lungcanceralliance.org
202-742-1422

SOURCE Lung Cancer Alliance

© 2012 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.